#News for #investors and #media: Today we have announced that one of our biologics has been approved in China as a treatment option for people with chronic rhinosinusitis with nasal polyps (#CRSwNP). Learn more here: https://www.gsk.com/en-gb/
Sobre nosotros
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Sitio web
-
http://www.gsk.com
Enlace externo para GSK
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- London, England
- Tipo
- Empresa pública
- Especialidades
- Pharmaceutical products y Vaccines
Ubicaciones
Empleados en GSK
Actualizaciones
-
Around 10 million people globally suffer from a severe cough that lasts more than a year. Yet research into the condition, known as refractory chronic cough, has been limited, despite it often leading to loss of sleep, depression, pain and social isolation. Thankfully, scientists are now working hard to address this unmet need. Read our article to find out how: https://gsk.to/3ORDRD5
-
Early signs and symptoms can help with the identification of respiratory infections like COVID-19, flu, and RSV – and indicate whether someone needs additional support from a healthcare professional. "When it comes to respiratory infections, the timing of symptoms can be a key indicator of their severity," says Professor Alberto Papi, Chair of Respiratory Medicine at the University of Ferrara. Symptoms of the flu, for example, tend to come on quickly, while RSV can take 4-6 days after infection before it becomes obvious. COVID-19 may show no or only mild symptoms for a few days after infection, only to escalate later. Take a look at our symptoms checker to find out what common experiences of these infections are 👇 And read our article to find out more here: https://lnkd.in/gSthY3k9
-
All patients should have access to the healthcare they deserve, regardless of who they are. To eliminate barriers to healthcare access, we’re fostering collaborations between expert organisations and underserved communities. By leading global partnerships for HIV treatment and vaccine awareness initiatives, we’re putting health equity at the forefront of what we do. Find out why closing the health equity gap is better for everyone 👇 https://gsk.to/3Bq24gC
-
“We had to rewire the organization, set it up for success, build our capabilities, and build our platforms” - our Chief Data and Technology Officer, Shobie Ramakrishnan, discusses how we're using data science and AI to reimagine what's possible for patients and society. Data and advanced tech are revolutionising how we discover, develop, and manufacture medicines and vaccines, with in-house capabilities driving progress and improving efficiencies across R&D, supply chains, and commercial operations. 🔗 Find out more in this article from Fortune: https://gsk.to/3BtP2Pf
-
Did you know we’re in the middle of a global outbreak of whooping cough? Thankfully, it is vaccine-preventable and would be less widespread were it not for the steady reduction in vaccine uptake we are seeing across the life course. In this article, Susie Barnes – SVP, Global Medical Affairs, Vaccines at GSK – explains why immunisation is one of the most cost-effective interventions available, and how, through ongoing prevention, we can protect ourselves throughout our lives. Read it here 👇 https://gsk.to/3DnXO1v